Companies Dominating the Morphine Landscape
- Verve Health Care Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mayne Pharma Group
- Daiichi Sankyo Company Limited
- Hikma Pharmaceuticals USA
- AbbVie Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Alcaliber S.A.
- Mallinckrodt Pharmaceuticals
- AstraZeneca plc
The competitive landscape of the morphine market is rapidly evolving as established key players, pharmaceutical giants and new entrants are investing in discovering novel medicines. Key players in the market are focused on developing new technologies and products catering to the stringent regulatory norms and consumer demand. These key players are adopting several strategies such as mergers and acquisitions, joint ventures, partnerships, and novel product launches to enhance their product base and strengthen their market position. Here are some key players operating in the global morphine market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Morphine Market in 2025 is assessed at USD 18.2 billion.
The global market size was valued at over USD 17.27 billion in 2024 and is expected to expand at a CAGR of around 6.7%, surpassing USD 40.13 billion revenue by 2037.
North America is on track to record USD 14.05 billion by 2037, attributed to a rising osteoporosis patient base and aging population.
The major players in the market include Verve Health Care Ltd., Mayne Pharma Group, Daiichi Sankyo Company Limited, Hikma Pharmaceuticals USA, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Alcaliber S.A., Mallinckrodt Pharmaceuticals, AstraZeneca plc
